ERBB2 and colonic neoplasm: In the present study, we reported a patient with locally advanced HER2-positive colon cancer who achieved pCR to four cycles of neoadjuvant chemotherapy combined with trastuzumab and pertuzumab, while experiencing only mild drug-related adverse events.